Section 1: Introductory Statements and Governance

1ISG-004

ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA

1ISG-013

Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation

1ISG-008

OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA

1ISG-012

ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB

1ISG-009

IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY

1ISG-007

ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?

1ISG-006

ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER

1ISG-003

IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS

1ISG-030

ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL

1ISG-029

CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS

1ISG-028

BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY

1ISG-027

CARBON FOOTPRINT OF A STERILISATION UNIT

1ISG-026

MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT'ANDREA HOSPITAL , VERCELLI

1ISG-025

BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB

1ISG-024

BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS

Pages